These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14513285)

  • 1. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab.
    Buda-Okreglak EM; Drabick JJ; Delaney NR
    Ann Hematol; 2004 Feb; 83(2):117-9. PubMed ID: 14513285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bing-Neel syndrome revealing Waldenström's macroglobulinemia].
    Drouet T; Behin A; Psimaras D; Choquet S; Guillevin R; Hoang Xuan K
    Rev Neurol (Paris); 2010 Jan; 166(1):66-75. PubMed ID: 19403149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of nasal skin necrosis associated with rituximab treatment for Waldenström's macroglobulinemia and subsequent spontaneous resolution.
    Pearlman AN; Fechner FP; Constantinides M
    Ear Nose Throat J; 2006 Jul; 85(7):431-3. PubMed ID: 16909812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
    Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
    Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
    Noronha V; Fynan TM; Duffy T
    J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
    Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
    Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
    Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
    Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
    Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
    Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute phase proteins in monoclonal gammapathies].
    Dubost JJ; Ristori JM; Soubrier M; Ruivard M; Sauvezie B
    Pathol Biol (Paris); 1991 Oct; 39(8):769-73. PubMed ID: 1722302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
    Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
    Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
    [No Abstract]   [Full Text] [Related]  

  • 15. Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
    Hałaburda K; Hellmann A
    Acta Haematol Pol; 1994; 25(1):63-7. PubMed ID: 8209618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
    J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
    Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
    Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
    Amin CJ; Rabinowitz I
    Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine in Waldenstrom's macroglobulinemia.
    Leblond V; Choquet S
    Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
    Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.